News FocusSWEDEN

Drug Research Endures the Pains of Globalization

See allHide authors and affiliations

Science  10 Dec 1999:
Vol. 286, Issue 5447, pp. 2063
DOI: 10.1126/science.286.5447.2063

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


STOCKHOLM-- Sweden's drug companies have joined the transnational drug industry, but their researchers are finding the global job market tough going. In 1995, Pharmacia merged with U.S.-based drug giant Upjohn, and since then the new company has cut its R&D personnel in Sweden by one-third, from 1500 to 1000. Last spring, Astra merged with Britain's Zeneca, and last week, the seemingly inevitable job cuts were announced: AstraZeneca plans to cut 450 positions from its research staff of 4000 in Sweden.